Holen Sie sich die Stockscreener-App
85.36
1.01%
-0.87
Handel nachbörslich:
85.36
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$86.23
Offen:
$86.665
24-Stunden-Volumen:
2.17M
Relative Volume:
0.49
Marktkapitalisierung:
$32.21B
Einnahmen:
$4.82B
Nettoeinkommen (Verlust:
$930.40M
KGV:
36.51
EPS:
2.3381
Netto-Cashflow:
$1.43B
1W Leistung:
-1.45%
1M Leistung:
-4.83%
6M Leistung:
+37.19%
1J Leistung:
+28.48%
1-Tages-Spanne:
$84.80
$86.67
1-Wochen-Bereich:
$84.80
$87.70
52-Wochen-Spanne:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
85.36 | 32.69B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
97.50 | 168.71B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.38 | 110.49B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Eingeleitet | Evercore ISI | In-line |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia - GlobeNewswire Inc.
RBC Raises Price Target on DexCom to $105 From $90, Keeps Outperform Rating - marketscreener.com
Behavioral Patterns of DXCM and Institutional Flows - Stock Traders Daily
Under a preset trading plan, DexCom (DXCM) EVP Sadie Stern sells 2,565 shares. - Stock Titan
Dexcom stock last trades at USD 86.68 on September 28, 2026 - AD HOC NEWS
Why DexCom Could Be the Big Winner Out of Oura’s IPO - Barron's
Dexcom Data Points to a CGM Awareness Gap, and Room to Grow - Medical Product Outsourcing
The Insider Report: The Leaders Have Taken Off - Benzinga
DexCom stock reports 13.1 percent revenue growth at USD 86.62 - AD HOC NEWS
Dexcom Publishes New Report During Easd 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - marketscreener.com
Tandem Diabetes Expands Insulin Delivery System to 12 New Countries - marketscreener.com
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care - The Joplin Globe
Dexcom stock slips 2.01 percent ahead of the open - AD HOC NEWS
DexCom (DXCM) Stock Looks Cheap Based On Future Cash Flow - Yahoo Finance
DexCom stock trades below its 52-week high as Truist lifts target - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is DexCom (DXCM) Cheap After Its Leadership Reshuffle Or Already Fairly Priced? - finance.yahoo.com
Dexcom stock falls 1.1 percent ahead of the open - AD HOC NEWS
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance UK
DexCom (DXCM) Promotes Former CFO Jereme Sylvain To Chief Operating Officer - Yahoo Finance
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
GlucoGuard, a Division of American Diversified Holdings (ADHC), Has Completed an Investors Deck Focused on Funding Research Required for FDA Approval - ACCESS Newswire
American Diversified Holdings Corporation (ADHC) Seeks Funding; Advances Dexcom App Integration - TradingView
Dexcom stock holds near its yearly high after Q2 growth - AD HOC NEWS
Dexcom stock heads into the open after Nasdaq gains 0.45 percent - AD HOC NEWS
Dexcom Inc. stock gains on strong Q2 2026 growth and solid diabetes-tech momentum - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings and Promising Growth in the Medical Device Sector - directorstalkinterviews.com
Dexcom stock heads into the open after a 1.61 percent gain - ad-hoc-news.de
Dexcom Inc. stock gains on leadership change and strong recent performance - AD HOC NEWS
Dexcom Inc. stock gains on fresh Truist and TD Cowen price targets - AD HOC NEWS
What Has Put DexCom (DXCM) Back in Focus? - Kalkine Media
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DXCM Maintained by Truist Securities -- Price Target Raised to $102 - GuruFocus
TD Cowen reiterates Buy rating on DexCom, $95 price target - TradingView
Dexcom Inc. stock gains as insider sales and valuation come into focus - ad-hoc-news.de
Dexcom stock heads into the open after a 0.68% Nasdaq gain - AD HOC NEWS
Dexcom Inc. stock edges higher as Truist Securities reiterates Buy rating - AD HOC NEWS
Truist Securities Adjusts DexCom Price Target to $102 From $93, Maintains Buy Rating - marketscreener.com
Dexcom stock heads into the open after a 1.0% gain - AD HOC NEWS
Dexcom Insider Sold Shares Worth $679,769, According to a Recent SEC Filing - marketscreener.com
Dexcom (NASDAQ: DXCM) director’s trust sells 8,089 shares in preset plan - Stock Titan
Dexcom (NASDAQ: DXCM) legal chief sells shares, keeps 99,885-share stake - Stock Titan
DexCom Inc (DXCM): GF Score of 95 Signals Strong Outperformance Potential - GuruFocus
Dexcom gives CFO Jereme Sylvain expanded role - MedTech Dive
Dexcom, Inc. Announces Appointment of Jereme Sylvain as Executive Vice President and Chief Operating Officer, Effective September 14, 2026 - marketscreener.com
Dexcom Promotes Jereme Sylvain to Chief Operating Officer - Yahoo Finance
Dexcom (DXCM) CFO trades stock under preset plan - Stock Titan
DexCom | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
DexCom Inc Share PriceDXCM, RNS News, Articles, Quotes, & Charts (NASDAQ:DXCM) - Proactive financial news
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom appoints Glenn Boehnlein to board of directors - The Globe and Mail
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):